Taysha Gene Therapies (TSHA) Research & Development (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Research & Development data on file, last reported at $33.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 117.21% year-over-year to $33.8 million; the trailing twelve-month figure through Mar 2026 stood at $21.2 million (up 619.16% YoY), and the FY2025 full-year result was $3.0 million, up 200.0% from the prior year.
• Research & Development grew to $33.8 million in Q1 2026, from -$58.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $38.2 million in Q1 2022 to a low of -$58.5 million in Q4 2025.
• A 5-year average of $7.8 million and a median of $15.6 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 419.48% in 2023 and surged 117.21% in 2026, its largest moves.
• Tracing TSHA's Research & Development over 5 years: stood at $12.7 million in 2022, then slumped by 419.48% to -$40.6 million in 2023, then dropped by 22.37% to -$49.7 million in 2024, then dropped by 17.66% to -$58.5 million in 2025, then soared by 157.84% to $33.8 million in 2026.
• Business Quant data shows TSHA's Research & Development at $33.8 million in Q1 2026, -$58.5 million in Q4 2025, and $25.7 million in Q3 2025.